“There is always a danger that health issues are not kept to the fore” in negotiations, says Niall Dickson
News
NICE turns down Darzalex combo for pre-treated multiple myeloma
Janssen says it is disappointed that NHS cost regulators are not backing NHS use of Darzalez (daratumumab) plus bortezomib and dexamethasone (DBd) for previously treated multiple myeloma in adults.
GSK sells psoriasis/dermatitis therapy to Dermavant
GlaxoSmithKline has sold rights to an experimental therapy being developed for psoriasis and dermatitis to Dermavant in a deal worth $330 million.
Zogenix’ drug cuts seizures in Dravet syndrome
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.
NHS under ‘intolerable’ strain
NHS Confederation chief executive Niall Dickson is warning that the NHS is “under intolerable strain”, after the latest performance data continue to show growing demand and missed targets.
Roche’s Venclexta filed in the US for acute myeloid leukemia
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
NICE backs Qarziba for children with high-risk neuroblastoma
NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
Pfizer re-organises into three business units
Pfizer has announced a re-organisation of its operations into three distinct businesses.
NICE backs use of dye for brain tumour removal
NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours.
NHS England appoints national clinical advisor for primary care
NHS England has appointed a specialist GP to encourage the spread of innovations that integrate health and social care throughout England.
Janssen launches PhII/III programme testing Tremfya in Crohn’s
Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease.
Gov’t launches £10 antimicrobial research competition
The government has launched a £10 million research competition to encourage the development of novel approaches to combating antimicrobial resistance and improving infection prevention and control.
Takeda gets US nod for Shire buy
Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire.
NICE advises restricted use of antibiotics for COPD
The National Institute for Health and Care Excellence is advising healthcare professionals to restrict use of antibiotics for chronic obstructive pulmonary disease (COPD).
